Yuji Murata
Osaka University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yuji Murata.
Maturitas | 2003
Masahide Ohmichi; Yuki Kanda; Koji Hisamoto; Kenichiro Morishige; Kazuhiro Takahashi; Kenjiro Sawada; Ryoko Minekawa; Keiichi Tasaka; Yuji Murata
OBJECTIVESnEstrogen acts directly on endothelial nitric oxide synthase through a non-genomic mechanism, resulting in rapid dilatation of blood vessels. In this study, we examined the change of endothelial function after surgical menopause.nnnMETHODSnIn 20 subjects who underwent gynecological operations (ovariectomy (OVX) 12, sham (SHAM) operation 8), postoperative changes of flow-mediated dilatation (FMD) of the brachial artery were examined using ultrasonography. Postoperative changes of the response to nitroglycerin (NTG) were also studied in these patients.nnnRESULTSnIn the OVX group, significant decreases of FMD were observed 1 week after the operation, although no changes were observed in the response to NTG. In the SHAM group, no remarkable changes of FMD or the response to NTG were observed after the operation.nnnCONCLUSIONSnOVX influences endothelium-dependent vasodilatation within as little as 1 week. Therefore, it may be important to address the rapid changes of circulation after surgical menopause in order to prevent cardiovascular disease.
Archives of Gynecology and Obstetrics | 2003
Ken-ichirou Morishige; Toshiya Yamamoto; Kenjiro Sawada; Masahide Ohmichi; Keiichi Tasaka; Yuji Murata
Abstract. Hormone replacement therapy (HRT) is effective treatment for postmenopausal bone loss and osteoporosis. However, postmenopausal women with low bone mass fail to respond after a few years of HRT and some postmenopausal women show no bone response to HRT. In these cases, additive therapy is necessary. Bisphosphonates are highly effective in postmenopausal osteoporosis. We investigated the effects of adding etidronate, a bisphosphonate, to HRT. The addition of etidronate to HRT improved bone density (4.40±1.12% increase per year) in patients showing no increase or even a decrease after at least 1 year of HRT (5.39±2.40% decrease per year).
Cancer Research | 2002
Kenjiro Sawada; Ken-ichirou Morishige; Masahiro Tahara; Rikako Kawagishi; Yoshihide Ikebuchi; Keiichi Tasaka; Yuji Murata
Gynecologic Oncology | 2002
Kenjiro Sawada; Ken-ichirou Morishige; Masahiro Tahara; Yoshihide Ikebuchi; Rikako Kawagishi; Keiichi Tasaka; Yuji Murata
American Journal of Physiology-cell Physiology | 2002
Yoko Okamoto; Masahiro Sakata; Kazuhiro Ogura; Toshiya Yamamoto; Masaaki Yamaguchi; Keiichi Tasaka; Hirohisa Kurachi; Masato Tsurudome; Yuji Murata
Endocrinology | 2004
Emi Arimoto-Ishida; Masahide Ohmichi; Seiji Mabuchi; Toshifumi Takahashi; Chika Ohshima; Jun Hayakawa; Akiko Kimura; Kazuhiro Takahashi; Yukihiro Nishio; Masahiro Sakata; Hirohisa Kurachi; Keiichi Tasaka; Yuji Murata
Cancer Research | 2005
Kae Hashimoto; Ken-ichirou Morishige; Kenjiro Sawada; Masahiro Tahara; Rikako Kawagishi; Yoshihide Ikebuchi; Masahiro Sakata; Keiichi Tasaka; Yuji Murata
Journal of Endocrinology | 2004
Takashi Takeda; Masahiro Sakata; Ryoko Minekawa; Toshiya Yamamoto; Masami Hayashi; Keiichi Tasaka; Yuji Murata
Biochemical and Biophysical Research Communications | 2004
Rikako Kawagishi; Masahiro Tahara; Kenjiro Sawada; Yoshihide Ikebuchi; Kenichiro Morishige; Masahiro Sakata; Keiichi Tasaka; Yuji Murata
American Journal of Obstetrics and Gynecology | 2005
Masahiro Tahara; Rikako Kawagishi; Kenjiro Sawada; Kenichiro Morishige; Masahiro Sakata; Keiichi Tasaka; Yuji Murata